12 Best Growth Stocks to Buy and Hold in 2025

Page 8 of 11

4. uniQure N.V. (NASDAQ:QURE)

Analyst Upside as of January 10, 2025: 57%

Number of Hedge Fund Holders: 24

uniQure N.V. (NASDAQ:QURE) is an emerging leader in gene therapy. The company’s platform is focused on liver and nervous system disorders. Its modular platform sets it apart from its competitors as it promises significant cost savings and efficient mode of operations.

QURE boasts a solid growth opportunity, with its revenue growing by $0.8 million in Q3 2024 from the same quarter in 2023. The stock’s growth trajectory can also be explained by its liquidity situation, after having retired nearly $50 million of its outstanding debt, reducing annual interest expense by almost $5 million.

The company is garnering immense traction for its accelerated performance in drug approvals. In the last quarter of 2024 alone, uniQure N.V. (NASDAQ:QURE) has processed several approvals and announced trials for its novel drugs. Its remarkable performance on the drugs and financial front explains why 24 hedge funds held stakes in QURE at the close of Q3 2024.

Page 8 of 11